DST-2970 (Abiraterone) for Prostate Cancer

"Clinicaltrials.gov states that this research program is currently in search of volunteers; its first appearance was on January 31st 2020, and it has recently been updated as of July 5th 2022."

"In order to move forward with this clinical trial, 54 suitable participants need to be enrolled. Potential enrollees can take part in the study at either University of Miami (Miami, Florida) or Icahn School of Medicine at Mount Sinai (New york, New York)."

"Patients may take part in this clinical trial at various institutions, including the University of Miami (Miami), Icahn School of Medicine at Mount Sinai (New york) and Carolina Urologic Research Center (Myrtle Beach). Additional sites are available."

"The safety of DST-2970 (Abiraterone) is rated as a 1 due to the limited evidence available from Phase 1 trials, which do not provide substantial proof for either efficacy or safety."

"As of now, 366 clinical trials researching DST-2970 (Abiraterone) are in progress. Of those, 100 have entered Phase 3 and the majority can be found near Duarte in California. Simultaneously, 1742 locations around the globe are running Abiraterone studies."

"DST-2970 (Abiraterone) is typically prescribed for patients suffering from thyroiditis. Its therapeutic effects can also be leveraged to manage other diseases, including ulcerative colitis, neoplastic conditions, and varicella-zoster virus induced acute retinal necrosis."

"This multi-phase medical trial, lasting for up to 18 months, will focus on Dose-Limiting Toxicity as a primary metric. The secondary objectives are measuring the efficacy of DST-2970 using modified RECIST 1.1 via Time to Progression (rTTP) and Change in Tumor Size assessments; additionally, trough levels at C1hour, C2hour and C3hour following daily oral administration of abiraterone will be monitored through Pharmacokinetic analysis."